Jump to content

COX-inhibiting nitric oxide donator: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Removal of interwiki links - all links transferred to Wikidata at d:Q2931854
Tag: Removal of all interwiki links; Wikidata is live
Alter: url, archive-url. URLs might have been anonymized. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.
 
(17 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{{Short description|Class of nonsteroidal anti-inflammatory drugs}}
'''COX-inhibiting nitric oxide donators''' ('''CINODs'''), also known as '''NO-NSAIDs''', are a new class of [[non-steroidal anti-inflammatory drug]] (NSAID) developed with the intention of providing greater safety than existing NSAIDs.
{{cs1 config|name-list-style=vanc}}
'''COX-inhibiting nitric oxide donators''' ('''CINODs'''), also known as '''NO-NSAIDs''', are a new class of [[nonsteroidal anti-inflammatory drug]] (NSAID) developed with the intention of providing greater safety than existing NSAIDs.<ref>{{cite journal | vauthors = Wallace JL, Reuter BK, Cicala C, McKnight W, Grisham MB, Cirino G | title = Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat | journal = Gastroenterology | date = 1994 | volume = 107 | pages = 172–179 | pmid= 8020659 | issue=1| doi = 10.1016/0016-5085(94)90074-4 }}</ref><ref>{{cite journal | vauthors = Wallace JL, Cirino G | title = The development of gastrointestinal-sparing anti-inflammatory drugs | journal = Trends Pharmacol Sci| date=1994 | volume=15 | pages=405–406| pmid= 7855901 | issue=11 | doi=10.1016/0165-6147(94)90083-3}}</ref><ref>{{cite journal | vauthors =Keeble JE, Moore PK | title = Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs | journal = Br J Pharmacol | date = 2002 | volume=137 | pages=295–310 | pmid=12237248 | doi=10.1038/sj.bjp.0704876 | issue=3 | pmc=1573498}}</ref><ref>{{cite journal | author = White, WB | title = Cardiovascular effects of the cyclooxygenase inhibitors | journal = Hypertension | date = 2007 | volume = 49 | issue = 3 | pages = 408–418 | pmid = 17261646 | doi = 10.1161/01.HYP.0000258106.74139.25 | doi-access = free }}</ref>


These compounds were first described by John Wallace<ref>[http://www.ucalgary.ca/irn/wallace.htm John Wallace, Professor, Department of Pharmacology and Therapeutics, University of Calgary]</ref> and colleagues. CINODs are [[Chemical compound|compound]]s generated by the fusion of an existing NSAID with a [[nitric oxide]] (NO)-donating [[functional group|moiety]] by chemical means, usually by [[Ester#Ester_reactions|ester linkage]]. CINODs retain the [[anti-inflammatory]] efficacy of NSAIDs via inhibition of [[cyclooxygenase]] (COX) while arguably improving upon gastric and vascular safety, most likely via [[vasorelaxation]], inhibition of [[leukocyte]] [[cell adhesion|adhesion]] and inhibition of [[caspases]], all known effects of NO.
These compounds were first described by John Wallace<ref>{{Cite web |url=https://www.ucalgary.ca/irn/wallace.htm |title=John Wallace, Professor, Department of Pharmacology and Therapeutics, University of Calgary |access-date=2017-08-25 |archive-date=2012-09-13 |archive-url=https://archive.today/20120913165358/http://www.ucalgary.ca/irn/wallace.htm |url-status=dead }}</ref> and colleagues. CINODs are [[Chemical compound|compound]]s generated by the fusion of an existing NSAID with a [[nitric oxide]] (NO)-donating [[functional group|moiety]] by chemical means, usually by [[Ester#Ester reactions|ester linkage]]. CINODs retain the [[anti-inflammatory]] efficacy of NSAIDs via inhibition of [[cyclooxygenase]] (COX) while arguably improving upon gastric and vascular safety, most likely via [[vasorelaxation]], inhibition of [[leukocyte]] [[cell adhesion|adhesion]] and inhibition of [[caspases]], all known effects of NO.


The first CINODs were developed in the 1990s, and as yet none have been approved for use by the general public. The importance of developing such drugs was increased when [[COX-2 inhibitor|COX-2-specific NSAIDs]] [[rofecoxib]] (Vioxx) and [[lumiracoxib]] (Prexige) were removed from major pharmaceutical markets in the mid-2000s due to [[COX-2 inhibitor#Risks and adverse effects|vascular safety concerns]]. In addition, traditional NSAIDs increase [[blood pressure]] and interfere with the actions of [[antihypertensive]] drugs. Several CINODs are currently being tested in [[clinical trials]], the most advanced of which are being conducted by the [[France|French]] [[pharmaceutical company]] [[NicOx]], whose flagship compound [[naproxcinod]] (NO-naproxen, nitronaproxen) is in [[clinical trials#Phase III|phase III trials]] for the treatment of [[osteoarthritis]].<ref>[http://www.drugdevelopment-technology.com/projects/azd3582/ HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation]</ref> Naproxcinod is a fusion of [[naproxen]] and a NO-donating group. Other CINODs are also being tested by NicOx for the treatment of diseases in which inflammation plays a role.<ref>[http://www.nicox.com/update/portfolio.html NicOx pipeline: product portfolio]</ref>
The first CINODs were developed in the 1990s, and as yet none have been approved for use by the general public. The importance of developing such drugs was increased when [[COX-2 inhibitor|COX-2-specific NSAIDs]] [[rofecoxib]] (Vioxx) and [[lumiracoxib]] (Prexige) were removed from major pharmaceutical markets in the mid-2000s due to [[COX-2 inhibitor#Risks and adverse effects|vascular safety concerns]]. In addition, traditional NSAIDs increase [[blood pressure]] and interfere with the actions of [[antihypertensive]] drugs. Several CINODs are currently being tested in [[clinical trials]], the most advanced of which are being conducted by the [[France|French]] [[pharmaceutical company]] [[NicOx]], whose flagship compound [[naproxcinod]] (NO-naproxen, nitronaproxen) is in [[clinical trials#Phase III|phase III trials]] for the treatment of [[osteoarthritis]].<ref>[http://www.drugdevelopment-technology.com/projects/azd3582/ HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation]</ref> Naproxcinod is a fusion of [[naproxen]] and a NO-donating group. Other CINODs are also being tested by NicOx for the treatment of diseases in which inflammation plays a role.<ref>{{Cite web |url=http://www.nicox.com/update/portfolio.html |title=NicOx pipeline: product portfolio |access-date=2007-12-27 |archive-url=https://web.archive.org/web/20071214171920/http://www.nicox.com/update/portfolio.html |archive-date=2007-12-14 |url-status=dead }}</ref>


==References==
==References==
{{Reflist}}
{{Reflist}}
* Wallace JL, Reuter BK, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. [[Gastroenterology]] 1994; 107: 172-179. PMID 8020659
* Wallace JL, Cirino G. The development of gastrointestinal-sparing anti-inflammatory drugs. [[Trends Pharmacol Sci]] 1994; 15: 405-406. PMID 7855901
* Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. [[Br J Pharmacol]] 2002;137:295-310. PMID 12237248
* White, WB. Cardiovascular effects of the cyclooxygenase inhibitors. [[Hypertension]] 2007; 49(3):408-18. PMID 17261646 [http://hyper.ahajournals.org/cgi/reprint/49/3/408]


<br>
{{NSAIDs}}
{{NSAIDs}}
{{Analgesics}}
{{Analgesics}}
{{Nitric oxide signaling}}


{{DEFAULTSORT:Cox-Inhibiting Nitric Oxide Donator}}
{{DEFAULTSORT:Cox-Inhibiting Nitric Oxide Donator}}

[[Category:Non-steroidal anti-inflammatory drugs]]
[[Category:Nonsteroidal anti-inflammatory drugs]]




Latest revision as of 06:38, 7 January 2024

COX-inhibiting nitric oxide donators (CINODs), also known as NO-NSAIDs, are a new class of nonsteroidal anti-inflammatory drug (NSAID) developed with the intention of providing greater safety than existing NSAIDs.[1][2][3][4]

These compounds were first described by John Wallace[5] and colleagues. CINODs are compounds generated by the fusion of an existing NSAID with a nitric oxide (NO)-donating moiety by chemical means, usually by ester linkage. CINODs retain the anti-inflammatory efficacy of NSAIDs via inhibition of cyclooxygenase (COX) while arguably improving upon gastric and vascular safety, most likely via vasorelaxation, inhibition of leukocyte adhesion and inhibition of caspases, all known effects of NO.

The first CINODs were developed in the 1990s, and as yet none have been approved for use by the general public. The importance of developing such drugs was increased when COX-2-specific NSAIDs rofecoxib (Vioxx) and lumiracoxib (Prexige) were removed from major pharmaceutical markets in the mid-2000s due to vascular safety concerns. In addition, traditional NSAIDs increase blood pressure and interfere with the actions of antihypertensive drugs. Several CINODs are currently being tested in clinical trials, the most advanced of which are being conducted by the French pharmaceutical company NicOx, whose flagship compound naproxcinod (NO-naproxen, nitronaproxen) is in phase III trials for the treatment of osteoarthritis.[6] Naproxcinod is a fusion of naproxen and a NO-donating group. Other CINODs are also being tested by NicOx for the treatment of diseases in which inflammation plays a role.[7]

References

[edit]
  1. ^ Wallace JL, Reuter BK, Cicala C, McKnight W, Grisham MB, Cirino G (1994). "Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat". Gastroenterology. 107 (1): 172–179. doi:10.1016/0016-5085(94)90074-4. PMID 8020659.
  2. ^ Wallace JL, Cirino G (1994). "The development of gastrointestinal-sparing anti-inflammatory drugs". Trends Pharmacol Sci. 15 (11): 405–406. doi:10.1016/0165-6147(94)90083-3. PMID 7855901.
  3. ^ Keeble JE, Moore PK (2002). "Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs". Br J Pharmacol. 137 (3): 295–310. doi:10.1038/sj.bjp.0704876. PMC 1573498. PMID 12237248.
  4. ^ White, WB (2007). "Cardiovascular effects of the cyclooxygenase inhibitors". Hypertension. 49 (3): 408–418. doi:10.1161/01.HYP.0000258106.74139.25. PMID 17261646.
  5. ^ "John Wallace, Professor, Department of Pharmacology and Therapeutics, University of Calgary". Archived from the original on 2012-09-13. Retrieved 2017-08-25.
  6. ^ HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation
  7. ^ "NicOx pipeline: product portfolio". Archived from the original on 2007-12-14. Retrieved 2007-12-27.


Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=COX-inhibiting_nitric_oxide_donator&oldid=1194104879"